78 reports of this reaction
1.6% of all AMPICILLIN SODIUM AND SULBACTAM SODIUM reports
#10 most reported adverse reaction
VOMITING is the #10 most commonly reported adverse reaction for AMPICILLIN SODIUM AND SULBACTAM SODIUM, manufactured by Roerig. There are 78 FDA adverse event reports linking AMPICILLIN SODIUM AND SULBACTAM SODIUM to VOMITING. This represents approximately 1.6% of all 4,969 adverse event reports for this drug.
Patients taking AMPICILLIN SODIUM AND SULBACTAM SODIUM who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is a less commonly reported adverse event for AMPICILLIN SODIUM AND SULBACTAM SODIUM, but still significant enough to appear in the safety profile.
In addition to vomiting, the following adverse reactions have been reported for AMPICILLIN SODIUM AND SULBACTAM SODIUM:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 78 FDA reports for AMPICILLIN SODIUM AND SULBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 1.6% of all adverse event reports for AMPICILLIN SODIUM AND SULBACTAM SODIUM, making it a notable side effect.
If you experience vomiting while taking AMPICILLIN SODIUM AND SULBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.